Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase IIb follow-up study of epratuzumab in active seropositive systemic lupus erythematosus after SL0007
2007-002589-37Phase 2Completed
- Sponsor
- UCB
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epratuzumab in systemic lupus erythematosus (SLE), sponsored by UCB. Primary endpoint: BILAG improvement without worsening in other organ systems. Started Jan 2008; status: completed.
02
Drugs
epratuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2007-002589-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002589-37.